Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
HHS secretary urges serious proposals from biopharma on enhancing price negotiation in Medicare Parts D and B, promising action from the Administration whether the industry cooperates or not.
Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.
Many of US drug pricing blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.
Many of blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.